

Supplemental Table 2: Associations between clinical, demographic, and treatment exposures and serum biomarkers among survivors of Hodgkin lymphoma.

	IL-6	TNF-a	OxLDL	MDA	GPx	hs-HS-CRP	Homocysteine
	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)	β (95%CI)
Female (vs. Male)	0.34 (-0.31,0.98)	-0.09 (-0.40,0.22)	0.05 (-0.12,0.22)	-0.36 (-0.95,0.22)	0.14 (-0.09,0.36)	-0.09 (-0.45,0.27)	-0.15 (-0.25,-0.05)*
Age at Diagnosis (per 1 year)	0.04 (-0.05,0.13)	0.03 (-0.02,0.07)	-0.01 (-0.04,0.01)	0.05 (-0.03,0.13)	-0.00 (-0.03,0.03)	-0.00 (-0.05,0.05)	0.00 (-0.01,0.02)
Time since Diagnosis (per 1 year)	0.08 (0.01,0.16)*	0.01 (-0.02,0.05)	0.01 (-0.01,0.03)	0.05 (-0.02,0.12)	0.00 (-0.02,0.03)	-0.01 (-0.05,0.03)	0.01 (-0.00,0.02)**
Cumulative Anthracycline Dose (per 100mg/m ²)	0.16 (-0.41,0.72)	-0.17 (-0.45,0.10)	0.01 (-0.14,0.16)	-0.05 (-0.56,0.46)	0.06 (-0.13,0.26)	-0.16 (-0.47,0.16)	0.03 (-0.06,0.11)
Cumulative Vinblastine/Vincristine Dose (per 100mg/m ²)	-0.42 (-2.40,1.57)	0.37 (-0.58,1.33)	0.12 (-0.40,0.64)	-0.72 (-2.51,1.08)	0.07 (-0.61,0.75)	1.11 (0.02,2.20)*	0.02 (-0.28,0.31)
Chest/Neck Radiation							
>30Gy vs <24Gy	0.13 (-0.93,1.19)	0.20 (-0.31,0.72)	0.15 (-0.12,0.43)	-0.61 (-1.57,0.35)	0.00 (-0.36,0.37)	0.65 (0.07,1.23)*	0.23 (0.07,0.39)*
24-30Gy vs <24Gy	-0.33 (-1.35,0.68)	-0.03 (-0.52,0.46)	0.05 (-0.22,0.31)	0.30 (-0.62,1.22)	-0.19 (-0.54,0.16)	0.17 (-0.39,0.73)	-0.06 (-0.21,0.09)
Bleomycin (Yes vs No)	-0.64 (-1.67,0.38)	0.11 (-0.39,0.60)	0.11 (-0.16,0.38)	-0.22 (-1.15,0.71)	0.20 (-0.15,0.55)	-0.29 (-0.87,0.28)	0.06 (-0.10,0.22)
Cyclophosphamide (Yes vs No)	0.17 (-0.59,0.93)	-0.15 (-0.51,0.22)	-0.05 (-0.25,0.15)	0.15 (-0.54,0.85)	-0.15 (-0.42,0.11)	0.13 (-0.29,0.56)	0.05 (-0.07,0.17)
Methotrexate IV (Yes vs No)	-0.73 (-1.77,0.32)	-0.23 (-0.73,0.28)	0.04 (-0.23,0.32)	-0.40 (-1.34,0.55)	0.16 (-0.20,0.52)	-0.23 (-0.83,0.36)	0.03 (-0.13,0.19)
Prednisone (Yes vs No)	0.56 (-0.60,1.73)	0.35 (-0.22,0.91)	0.03 (-0.28,0.33)	0.74 (-0.32,1.79)	-0.21 (-0.61,0.19)	0.20 (-0.44,0.85)	0.12 (-0.06,0.29)
Development of Secondary Neoplasm (Yes vs No)	-0.16 (-0.96,0.65)	-0.03 (-0.42,0.36)	-0.03 (-0.24,0.18)	-0.17 (-0.91,0.56)	-0.23 (-0.50,0.05)	0.09 (-0.36,0.54)	-0.12 (-0.24,0.01)

* indicates p<0.05; ** indicates p<0.10

Biomarkers were natural log transformed and results reported have not been back-transformed. All of the factors above were included in one multivariate model for each biomarker outcome, models were additionally adjusted for age, race, smoking, BMI, anti-inflammatory/steroid, recent infection.

Supplemental Table 2 Continued:

	Absolute Lymphocyte Count	Platelets
Female (vs. Male)	-0.00(-0.12,0.12)	0.07(-0.01,0.15)
Age at Diagnosis (per 1 year)	-0.01(-0.03,0.01)	0.00(-0.01,0.01)
Time since Diagnosis (per 1 year)	-0.01(-0.03,0.00)	0.00(-0.01,0.01)
Cumulative Anthracycline Dose (per 100mg/m ²)	-0.04(-0.14,0.07)	0.00(-0.07,0.07)
Cumulative Vinblastine/Vincristine Dose (per 100mg/m ²)	0.25(-0.13,0.62)	-0.04(-0.29,0.21)
Chest/Neck Radiation		
>30Gy vs <24Gy	-0.20(-0.40,0.00)**	-0.15(-0.28,-0.02)*
24-30Gy vs <24Gy	-0.11(-0.29,0.08)	-0.09(-0.21,0.04)
Bleomycin (Yes vs No)	-0.03(-0.22,0.16)	0.01(-0.12,0.14)
Cyclophosphamide (Yes vs No)	-0.13(-0.27,0.01)	0.01(-0.08,0.11)
Methotrexate IV (Yes vs No)	-0.08(-0.28,0.11)	-0.04(-0.17,0.09)
Prednisone (Yes vs No)	-0.31(-0.53,-0.08)*	-0.15(-0.30,-0.01)*
Development of Secondary Neoplasm (Yes vs No)	-0.10(-0.25,0.05)	-0.03(-0.13,0.07)
<p>* indicates p<0.05; ** indicates p<0.10 Biomarkers were natural log transformed and results reported have not been back-transformed. All of the factors above were included in one multivariable model for each biomarker outcome, models were additionally adjusted for age, race, smoking, BMI, anti-inflammatory/steroid, recent infection.</p>		